- Kindeva has opened its new UK headquarters at Charnwood Campus Science Innovation and Technology Park, Loughborough.
- The 150,000 sq. ft. facility will expand metered-dose inhaler (MDI) services and support next-generation propellant development.
Kindeva, a global CDMO and drug delivery specialist, has officially opened its new UK headquarters at Charnwood Campus Science Innovation and Technology Park, Loughborough. The site marks a major expansion of the company’s metered-dose inhaler (MDI) services, focusing on the development and testing of next-generation propellants (NGPs).
The 150,000 sq. ft. facility offers services across the drug development cycle, including early-stage viability, analytical method development, and commercial analysis. It also houses a Chemistry, Manufacturing and Controls (CMC) strategy and regulatory department to support customers navigating complex compliance requirements.
The opening ceremony was hosted by Kindeva CEO Milton Boyer and David Northage, Mayor of Charnwood. The event included a ribbon-cutting and site tour, during which the company outlined its investment and recruitment strategy.
Boyer said: “The opening of our Loughborough Headquarters marks a significant milestone in Kindeva’s growth strategy as we continue to innovate, scale, and expand our global footprint.”
The headquarters will also lead the company’s efforts in NGP development as the pharmaceutical industry prepares for legislative changes to reduce the environmental impact of current inhaler propellants. Boyer added that inhalers contribute 0.03% of global greenhouse gas emissions and 3% of the NHS carbon footprint, noting that the new site will help Kindeva drive sustainability and ensure supply continuity during the transition to low Global Warming Potential (GWP) propellants.
